title: Use of lipid-lowering medications in myasthenia gravis: a case report and literature review.
abstract: We present a patient with myasthenia gravis (MG) who developed worsening of his condition after starting ezetimibe. We review the literature concerning lipid-modifying medications and MG. The use of bile acid sequestrant agents may have a place in the lipid management of MG patients because they did not seem to cause muscle-related side effects or worsening of MG.
authors.affiliation: Department of Clinical Biochemistry, Lewisham Hospital NHS Trust, London, UK; Guy's Hospital, Southwark, London, UK.
authors.forename: Sophie C
authors.initials: SC
authors.lastname: Ragbourne
authors.affiliation: Department of Clinical Biochemistry, Lewisham Hospital NHS Trust, London, UK; Department of Metabolic Medicine, University Hospital Lewishsam, London, UK; Guy's Hospital, Southwark, London, UK; St Thomas' Hospital, Lambeth, UK; University of Greenwich, London, UK. Electronic address: m.crook@nhs.net.
authors.forename: Martin A
authors.initials: MA
authors.lastname: Crook
mesh_terms: D000069438:Ezetimibe / Q000009:adverse effects*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000175:diagnosis / Q000473:pathology*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000069438:Ezetimibe
keywords: Ezetimibe; Hyperlipidemia; Myasthenia gravis; Statins; myopathy